Long-term effectiveness of the immunotherapy of anal condyloma acuminatum

Abstract

In a seven-year period, 200 patients with persistent or recurrent anal and perianal condyloma acuminatum were treated by immunotherapy. There were 120 primary and 80 recurrent cases in the study. Autogenous vaccine was prepared for each patient and injected subcutaneously, 0.5 ml weekly, for six weeks. Excellent results were seen in 84 per cent, fair results in 11 per cent and no benefit in 5 per cent of patients. No adverse reactions or complications were encountered. Long-term follow-up (average 46 months) was possible for 86 per cent of the patients, all of whom remained disease free. Immunotherapy is the recommended method of treatment for extensive, recurrent, or persistent anal condyloma acuminatum.